Outcome of pharmacological treatments of pathological gambling: A review and meta-analysis

Journal of Clinical Psychopharmacology

Volumn 27, Issue 4, 2007, Pages 357-364

  Pallesen, Ståle ^a   Molde, Helge ^a   Arnestad, Helga Myrseth ^a   Laberg, Jon Christian ^a   Skutle, Arvid ^a   Iversen, Erik ^a   Støylen, Inge Jarl ^a   Kvale, Gerd ^a   Holsten, Fred ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUVOXAMINE; LITHIUM CARBONATE; MOOD STABILIZER; NALMEFENE; NALTREXONE; NEFAZODONE; OPIATE ANTAGONIST; PAROXETINE; SERTRALINE; TOPIRAMATE; VALPROIC ACID;

CLINICAL TRIAL; CONFIDENCE INTERVAL; EFFECT SIZE; HUMAN; MEDLINE; MULTIPLE REGRESSION; OUTCOME ASSESSMENT; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PSYCINFO; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; GAMBLING; HUMANS; MODELS, STATISTICAL; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; REGRESSION ANALYSIS;

EID: 34447539851     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.013e3180dcc304d     Document Type: Review

References (45)

1. Bolen DW, Boyd WH. Gambling and the gambler. A review and preliminary findings. Arch of Gen Psychiatry. 1968;18:617-630.
2. Shaffer HJ, Hall MN, Vander Bilt J. Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health. 1999;89:1369-1376.
3. Pallesen S, Mitsem M, Kvale G, et al. Outcome of psychological treatments of pathological gambling: a review and meta-analysis. Addiction. 2005;100:1412-1422.
4. Hollander E, Kaplan A, Pallanti S. Pharmacological treatments. In: Grant JE, Potenza MN, eds. Pathological Gambling: A Clinical Guide to Treatment. Washington, DC: American Psychiatric Publishing; 2004:189-205.
5. Blanco C, Ibáñez A, Sáiz-Ruiz J, et al. Epidemiology, pathophysiology and treatment of pathological gambling. CNS Drugs. 2000;13:397-407.
6. Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry. 2002;63:559-564.
7. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol. 2003;18:243-249.
8. Blanco C, Petkova E, Ibáñez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry. 2002;14:9-15.
9. Crisp BR, Thomas SA, Jackson AC, et al. Not the same: a comparison of female and male clients seeking treatment from problem gambling counselling services. J Gambl Stud. 2004;20:283-299.
10. de Castro IP, Ibáñez A, Torres P, et al. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics. 1997;7:345-348.
11. Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry. 2005;162:137-145.
12. Crockford DN, El-Guebaly N. Naltrexone in the treatment of pathological gambling and alcohol dependence. Can J Psychiatry. 1998;43:86.
13. de la Gandara JJ. Fluoxetine: open-trial in pathological gambling (Abstract). Presented at the 152 Annual Meeting of American Psychiatric Association; May 16-21; Washington, DC; 1999.
14. Ladouceur R, Sylvain C, Boutin C, et al. Group therapy for pathological gamblers: a cognitive approach. Behav Res Ther. 2003;41:587-596.
15. Grant JE, Kim SW. Effectiveness of pharmacotherapy for pathological gambling: a chart review. Ann Clin Psychiatry. 2002;14:155-161.
16. Black DW. An open-label trial of bupropion in the treatment of pathological gambling. J Clin Psychopharmacol. 2004;24:108-110.
17. Dannon PN, Lowengrub K, Gonopolski Y, et al. Topirmate versus fluvoxamine in the treatment of pathological gambling. Clin Neuropharmacol. 2005;28:6-10.
18. Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol. 2005;26:593-596.
19. Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303-312.
20. Grant JE, Potenza MN. Escitalopramtreatment of pathological gambling with co-occuring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006;21:203-209.
21. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiarty. 2000;47:813-817.
22. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol. 2001;16:285-289.
23. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914-921.
24. Kim SW, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:501-507.
25. Pallanti SR, Rossi NB, Sood E, et al. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry. 2002;63:1034-1039.
26. Sáiz-Ruiz J, Blanco C, Ibáñes A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry. 2005;66:28-33.
27. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63:45-48.
28. Hedges LV. Fixed effects models. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:285-99.
29. Wolf FM. Meta-Analysis. Quantitative Methods for Research Synthesis. Beverly Hills, CA: Sage Publications; 1986.
30. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. J Am Med Dir Assoc. 1999;282:1054-1060.
31. Robinson LA, Berman JS, Neimeyer RA. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychol Bull. 1990;108:30-49.
32. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press; 1985.
33. Durlak JA, Lipsey MW. A practitioner's guide to meta-analysis. Am J Community Psychol. 1991;19:291-332.
34. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Rev ed. New York, NY: Academic Press; 1977.
35. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull. 1979;86:638-641.
36. Johnson BT. DSTAT: Software for the Meta-Analytic Review of Research Literatures. Hillsdale, NJ: Erlbaum; 1989.
37. Norhus IH, Pallesen S. Psychological treatment of late-life anxiety: an empirical review. J Consult Clin Psychol. 2003;71:643-651.
38. Walker M, Toneatto T, Potenza MN, et al. A framework for reporting outcomes in problem gambling treatment research: The Banff, Alberta Consensus. Addiction. 2006;101:504-511.
39. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change - applications to addictive behaviors. Am Psychol. 1992;47:1102-1114.
40. Desai RA, Maciejewski PK, Pantalon MV, et al. Gender differences in adolescent gambling. Ann Clin Psychiatry. 2005;17:249-258.
41. Tavares H, Martins SS, Lobo DSS, et al. Factors at play in faster progression for female pathological gamblers: an explanatory analysis. J Clin Psychiatry. 2003;64:433-438.
42. Petry NM, Steinberg KL. Childhood maltreatment in male and female treatment-seeking pathological gamblers. Psychol Addict Behav. 2005;19:226-229.
43. Ibáñez A, De Castro IP, Fernández-Piqueras J, et al. Pathological gambling and DNA polymorphic markers at MAO-A and MAO-B genes. Mol Psychiatry. 2002;5:105-109.
44. Lee S, Walker JR, Jakul L, et al. Does elimination of placebo responders in a placebo run increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety. 2004;19:10-19.
45. Kim SW, Grant JE. The psychopharmacology of pathological gambling. Semin Clin Neuropsychiatry. 2001;6:184-195.